During the last session, Summit Therapeutics Inc (NASDAQ:SMMT)’s traded shares were 2.44 million, with the beta value of the company hitting -1.15. At the end of the trading day, the stock’s price was $3.88, reflecting an intraday gain of 9.60% or $0.34. The 52-week high for the SMMT share is $5.22, that puts it down -34.54 from that peak though still a striking 66.49% gain since the share price plummeted to a 52-week low of $1.30. The company’s market capitalization is $2.72B, and the average intraday trading volume over the past 10 days was 2.49 million shares, and the average trade volume was 2.36 million shares over the past three months.

Summit Therapeutics Inc (NASDAQ:SMMT) trade information

Summit Therapeutics Inc (SMMT) registered a 9.60% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 9.60% in intraday trading to $3.88, hitting a weekly high. The stock’s 5-day price performance is -6.28%, and it has moved by -19.83% in 30 days. Based on these gigs, the overall price performance for the year is 140.99%. The short interest in Summit Therapeutics Inc (NASDAQ:SMMT) is 16.96 million shares and it means that shorts have 6.85 day(s) to cover.

Summit Therapeutics Inc (SMMT) estimates and forecasts

Statistics show that Summit Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Summit Therapeutics Inc (SMMT) shares have gone up 115.56% during the last six months, with a year-to-date growth rate less than the industry average at -84.62% against 9.20.

While earnings are projected to return 75.76% in 2024.

SMMT Dividends

Summit Therapeutics Inc is due to release its next quarterly earnings between May 09 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Summit Therapeutics Inc (NASDAQ:SMMT)’s Major holders

Summit Therapeutics Inc insiders own 88.13% of total outstanding shares while institutional holders control 4.80%, with the float percentage being 40.47%. Blackrock Inc. is the largest shareholder of the company, while 142 institutions own stock in it. As of Jun 29, 2023, the company held over 8.76 million shares (or 1.26% of all shares), a total value of $21.99 million in shares.

The next largest institutional holding, with 6.3 million shares, is of Baker Brothers Advisors, LLC’s that is approximately 0.90% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $15.82 million.

Also, the Mutual Funds coming in first place with the largest holdings of Summit Therapeutics Inc (SMMT) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 3.66 million shares. This amounts to just over 0.52 percent of the company’s overall shares, with a $9.19 million market value. The same data shows that the other fund manager holds slightly less at 2.66 million, or about 0.38% of the stock, which is worth about $4.31 million.